Rigel Pharmaceuticals Inc. has provided its financial outlook for 2026, projecting full-year total revenue of approximately $275 to $290 million, with net product sales expected to range from $255 to $265 million. The company anticipates reporting positive net income for the full year 2026. This outlook follows a strong performance in 2025, highlighted by record net product sales and total fourth quarter revenue of approximately $69.8 million, up from $57.6 million in the same period of 2024. The company also reported significant financial progress in 2025, including continued profitability and the generation of $77 million in cash.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rigel Pharmaceuticals Inc. published the original content used to generate this news brief on January 12, 2026, and is solely responsible for the information contained therein.